Paper36908849
Emerging Therapeutic Targets for Portal Hypertension.
Felli E and 5 others. Curr Hepatol Rep, 2023. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Emerging Therapeutic Targets for Portal Hypertension. Papers, record 36908849. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36908849
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References205
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31563219 | Pharmacologic Management of Portal Hypertension. | Clin Liver Dis | 2019 | https://conductscience.org/library/papers/31563219 | PubMed |
| 2 | 23216382 | Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. | J Gastroenterol Hepatol | 2013 | https://conductscience.org/library/papers/23216382 | PubMed |
| 3 | 19157625 | Angiogenesis in liver disease. | J Hepatol | 2009 | https://conductscience.org/library/papers/19157625 | PubMed |
| 4 | 33128017 | Molecular and cellular mechanisms of liver fibrosis and its regression. | Nat Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/33128017 | PubMed |
| 5 | 10347107 | Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. | Hepatology | 1999 | https://conductscience.org/library/papers/10347107 | PubMed |
| 6 | 34165199 | Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. | Aliment Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34165199 | PubMed |
| 7 | 30905652 | Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. | Gastroenterology | 2019 | https://conductscience.org/library/papers/30905652 | PubMed |
| 8 | 29099421 | Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. | Eur J Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/29099421 | PubMed |
| 9 | 34606912 | Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? | J Hepatol | 2022 | https://conductscience.org/library/papers/34606912 | PubMed |
| 10 | 28953991 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. | Braz J Med Biol Res | 2017 | https://conductscience.org/library/papers/28953991 | PubMed |
| 11 | 22365955 | Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. | Life Sci | 2012 | https://conductscience.org/library/papers/22365955 | PubMed |
| 12 | 22806357 | Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. | Hepatology | 2012 | https://conductscience.org/library/papers/22806357 | PubMed |
| 13 | 8995940 | Long course and prognostic factors of virus-induced cirrhosis of the liver. | Am J Gastroenterol | 1997 | https://conductscience.org/library/papers/8995940 | PubMed |
| 14 | 31607677 | Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/31607677 | PubMed |
| 15 | 17016424 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/17016424 | PubMed |
| 16 | 26406236 | Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. | PLoS One | 2015 | https://conductscience.org/library/papers/26406236 | PubMed |
| 17 | 35120736 | Baveno VII - Renewing consensus in portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35120736 | PubMed |
| 18 | 25500203 | KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. | Gut | 2015 | https://conductscience.org/library/papers/25500203 | PubMed |
| 19 | 24232462 | Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. | Nat Rev Immunol | 2013 | https://conductscience.org/library/papers/24232462 | PubMed |
| 20 | 33106416 | Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/33106416 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41659769 | Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats. | JHEP Rep | 2026 | https://conductscience.org/library/papers/41659769 | PubMed |
| 41024757 | Advances in portal hypertension management: Evolution of the Baveno guidelines. | World J Gastroenterol | 2025 | https://conductscience.org/library/papers/41024757 | PubMed |
| 40689145 | Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease. | JHEP Rep | 2025 | https://conductscience.org/library/papers/40689145 | PubMed |
| 40404839 | Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/40404839 | PubMed |
| 40069401 | Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/40069401 | PubMed |
| 40044498 | Vasomics of the liver. | Gut | 2025 | https://conductscience.org/library/papers/40044498 | PubMed |
| 39997697 | From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension. | Metabolites | 2025 | https://conductscience.org/library/papers/39997697 | PubMed |
| 39870944 | Preventing the progression of cirrhosis to decompensation and death. | Nat Rev Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39870944 | PubMed |
| 39859028 | Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy-From Fundamentals to Applied Tactics. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39859028 | PubMed |
| 39640222 | Mechanisms and implications of recompensation in cirrhosis. | JHEP Rep | 2024 | https://conductscience.org/library/papers/39640222 | PubMed |
| 38860875 | Microarray analysis demonstrates up-regulation of the endothelin-1 gene with compensatory down-regulation of the ETA receptor gene in human portal vein. | Biosci Rep | 2024 | https://conductscience.org/library/papers/38860875 | PubMed |
| 38447532 | Examining the therapeutic landscape of beta-blockers in portal hypertension. | Clin Mol Hepatol | 2024 | https://conductscience.org/library/papers/38447532 | PubMed |
Genes38
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36908849
GET https://conductscience.org/api/papers/v1/36908849/references?page=2